Trials / Unknown
UnknownNCT03742544
Post Marketing Surveillance of Telostop TAB (Telmisartan/Rosuvastatin) for Evaluating the Safety and Efficacy
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 600 (estimated)
- Sponsor
- IlDong Pharmaceutical Co Ltd · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Post-marketing surveillance of Telostop TAB (Telmisartan/Rosuvastatin)
Detailed description
Telostop TAB is fixed-dose combination of telmisartan and rosuvastatin, which was approved in 2015 in the Republic of Korea for the treatment of patients with hypertention and dyslipidemia. A post-marketing surveillance was conducted following the approval to obtain data on the safety and efficacy of Telostop TAB in real-world practice.
Conditions
Timeline
- Start date
- 2015-06-23
- Primary completion
- 2020-10-30
- Completion
- 2020-10-30
- First posted
- 2018-11-15
- Last updated
- 2018-11-15
Source: ClinicalTrials.gov record NCT03742544. Inclusion in this directory is not an endorsement.